Danaher Completes Acquisition of Abcam to Strengthen Life Sciences Portfolio

Dec 08, 2023 08:27 CST Updated 08:27

Danaher

Product Design and Manufacturer

Abcam

Developer of Life Science Reagents and Tools

About Danaher

At Danaher, we harness the power of science, technology, and operations to accelerate the impact of tomorrow's innovations on today’s world. We collaborate with customers worldwide to develop solutions that address their most complex challenges, turning the potential of science into reality. Our global team is shaping the future of life sciences, medical diagnostics, biotechnology, and more.

About Danaher Life Sciences Platform

Danaher Life Sciences Platform serves the world's leading life sciences companies, accelerating breakthrough innovations to achieve healthier lives for humanity. We maintain long-term collaborations with scientists from research, clinical, and government institutions, applying our expertise in science and operations to help them gain deeper insights into disease mechanisms and develop more effective treatments and efficient workflows. Together, we accelerate the positive impact of life sciences on human life.

E.N.D

Recommended articles from previous issues:

Eight Companies in China Complete New Round of Financing, Accelerating Advancement of Cell and Gene Therapies

Rongcan Bio Completes Over 100 Million Yuan in Series A Financing

"Cancer Risk" of CAR-T Therapy May Face Stricter Regulation

63.95 Million Yuan! Shanghai Makes a Generous Investment in Key Special Projects like Gene Editing, Synthetic Biology, and Computational Biology

Professor Renjie Chai's Research Team at Southeast University Makes New Progress in the Development of AAV Gene Therapy Drugs for Hereditary Deafness

Chinese Academy of Sciences Releases 128 Scientific Research Frontiers, Including Gene Therapy for Genetic Diseases, Tumor Immunotherapy, and Gene Editing Technology

Sino Biopharma Secures Nearly 600 Million Yuan in A+ Round Funding, Led by Tencent Investment and OrbiMed China

Academician Huanming Yang: The Design and Synthesis of Genomes May Become the Third Major Event in Life Science

CSPC's First siRNA Drug Targeting PCSK9 Approved for Clinical Trials!

$32,000/Bottle! BioMarin's Hemophilia AAV Gene Therapy Launches in Germany

Zhang Jin's Team Reports the Latest Achievements in Second-Generation CAR-Macrophage Anti-Solid Tumor Therapy

Moderna's First mRNA Drug Factory in China Breaks Ground

He Yuan Biologics CAR-T Product Priced at 999,000 RMB per Dose

Disclaimer: This article is sourced from Danaher's official channels. The purpose of this article is for knowledge sharing. All content is for reference only and does not constitute any recommendations.